Oncolytics Biotech, Coherus Plan Pelareorep–LOQTORZI Study in Anal Cancer
阅读少于1分钟
Oncolytics Biotech signed a clinical supply agreement with Coherus Oncology to evaluate pelareorep with LOQTORZI in second-line squamous cell anal carcinoma.
Key Highlights:
- The planned study is expected to begin in Q1 2027 at a U.S. cancer center that will be named once the study commences.
- It is expected to enroll patients whose cancer progressed after first-line chemotherapy and checkpoint inhibition; no second-line therapy is approved for this indication.
- Coherus will provide LOQTORZI for the study, and Oncolytics expects to partner with the sponsoring institution.
- The combination will assess whether pelareorep’s immune activation can enhance PD-1 blockade; supportive results could inform evaluation across HPV-associated cancers.
Original SEC Filing: ONCOLYTICS BIOTECH INC [ ONCY ] - 8-K - Nov. 12, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.